US2019241969A1PendingUtilityA1
Compositions and methods for diagnosing thyroid tumors
Assignee: PONTIFICA UNIV CATOLICA DE CHILEPriority: Nov 27, 2012Filed: Feb 15, 2019Published: Aug 8, 2019
Est. expiryNov 27, 2032(~6.3 yrs left)· nominal 20-yr term from priority
A61P 35/00C12Q 2600/158A61N 5/10G01N 2800/046C12Q 1/6886C12Q 2600/16G01N 33/68G01N 33/5758
33
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides diagnostic assays for identifying thyroid cancer in a biological sample, including a fine needle aspirate, as well as related compositions and kits useful in practicing the methods of the invention.
Claims
exact text as granted — not AI-modified1 - 57 . (canceled)
58 . A method of diagnosing thyroid cancer in a subject comprising:
(a) determining an expression level of gene products in a thyroid tissue sample obtained from the subject, the gene products comprising gene products expressed by the CXCR3, CCR3, CXCL10, CK19, TIMP-1, CLDN-1, CAR, XB-130, HO-1 and CCR7 genes; and (b) diagnosing the thyroid cancer in the subject using a classifier algorithm trained to stratify samples based upon the expression levels of said gene products into two groups identified as:
(i) an outlier sample having an outlier expression level for at least one of said gene products as compared to a cancer or non-cancer reference expression level for the same gene product, wherein an outlier expression level is defined as a gene expression level that is greater than two standard deviations from the cancer or non-cancer reference expression level for that respective gene product; and
(ii) a non-outlier sample having no such outlier expression levels for said gene products;
(c) wherein,
(i) if the sample is identified as an outlier sample in step (b)(i), a first classifier algorithm is applied to classify the outlier sample as cancerous or non-cancerous, wherein the first algorithm was trained on the expression level of said gene products in a plurality of known cancer or non-cancer outlier samples; and
(ii) wherein if the tissue sample was identified as a non-outlier sample in step (b), a second classifier algorithm is applied to classify the sample as cancerous or non-cancerous; wherein the second algorithm was trained on the expression level of said gene products in a plurality of known cancer or non-cancer non-outlier samples.
59 . The method of claim 58 , wherein classification output data from tissue samples classified in steps (c)(i) and (c)(ii) is integrated by an algorithm to report the probability of a cancer or benign result.
60 . The method of claim 58 , wherein the second classifier algorithm comprises a linear discriminant analysis.
61 . The method of claim 58 , wherein the gene products are RNA.
62 . The method of claim 58 , wherein the gene products are protein.
63 . The method of claim 58 , further comprising the step of performing a cytological analysis on a thyroid tissue sample obtained from the subject prior to (a) to obtain a preliminary diagnosis.
64 . The method of claim 63 , wherein samples with a preliminary diagnosis of intermediate or indeterminate are further analyzed by the methods of step (a) and step (b).
65 . The method of claim 58 , further comprising obtaining the thyroid tissue sample from the subject.
66 . A method of diagnosing thyroid cancer in a subject comprising:
(a) determining an expression level of gene products in a thyroid tissue sample obtained from the subject, the gene products consisting of gene products expressed by the CXCR3, CCR3, CXCL10, CK19, TIMP-1, CLDN-1, CAR, XB-130, HO-1 and CCR7 genes; and (b) identifying the thyroid tissue sample as cancerous or benign by correlating the expression levels determined in (a) with the presence or absence of thyroid cancer in the thyroid tissue sample; wherein the correlating is performed using a classifier generated using gene expression data determined for the gene products from a plurality of normal thyroid tissue samples and cancerous thyroid tissue samples; wherein the thyroid tissue sample is identified as cancerous or benign with: a sensitivity of greater than or equal to 92% or greater than or equal to 97%; a specificity of greater than or equal to 60% or greater than or equal to 90%; a positive predictive value of greater than or equal to 50% or greater than or equal to 90%; a negative predictive value of greater than or equal to 92% or greater than or equal to 94%; a positive likelihood ratio of greater than or equal to 2 or greater than or equal to 10; a positive post-test probability of greater than or equal to 50% or greater than or equal to 80%; a negative likelihood ratio of less than or equal to 0.14 or less than or equal to 0.08; or a negative post-test probability of less than or equal to 7.0% or less than or equal to 3.0%/.
67 . The method of claim 66 , wherein the correlating of (b) comprises comparing the expression levels determined in (a) to gene expression data determined for the gene products in the following two sets of biological samples:
(i) a plurality of normal thyroid tissue samples; and (ii) a plurality of cancerous thyroid tissue samples,
wherein the thyroid tissue sample is identified as cancerous if there is a difference in the expression level of the gene products between the thyroid tissue sample and the gene expression data of (i), or if there is no significant difference in the expression level of the gene products between the thyroid tissue sample and the gene expression date of (ii).
68 . The method of claim 66 , wherein the classifier identifies atypical CT values followed by linear discriminant analysis.
69 . The method of claim 66 , wherein the gene products are RNA.
70 . The method of claim 66 , wherein the gene products are protein.
71 . The method of claim 66 , further comprising the step of performing a cytological analysis on a thyroid tissue sample obtained from the subject prior to (a) to obtain a preliminary diagnosis.
72 . The method of claim 71 , wherein samples with a preliminary diagnosis of intermediate or indeterminate are further analyzed by the methods of step (a) and step (b).
73 . The method of claim 66 , further comprising obtaining the thyroid tissue sample from the subject.Join the waitlist — get patent alerts
Track US2019241969A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.